Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

Efficacy and Safety in Hepatitis C Recurrence Therapy

PROTECT. Pegylated Interferon alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy

Purpose:

The primary endpoint for this study will be to determine the sustained virologic response (SVR) at the 24-week follow up after treatment with PEG-IFN -2b and Ribavirin in post-orthotopic liver transplant (OLT) recipients with recurrent HCV.

Inclusion Criteria:

Patients whom have had a liver transplant for end stage liver disease due to recurrent HCV.

Sponsor:

Integrated Therapeutics/ Schering Plough

Principle Investigator:

Laura Kulik, MD

Cost:

None

Contact:

Karen Matijevich, RN
312-503-5213

Last UpdateMarch 25, 2011
top